Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Want to invest ethically for a brighter future?
(but still make lots of money)?

Want to invest ethically for a brighter future? (but still make lots of money)?

 Take Rask’s FREE Ethical Investing course today.

  • Online & 100% free
  • ETFs, shares & Super
Want to invest ethically for a brighter future? 
(but still make lots of money)?

 Take Rask’s FREE online Ethical Investing course.

Why the Volpara (ASX:VHT) share price is rising

The Volpara Health Technologies Ltd (ASX: VHT) share price is going up after the healthcare business revealed patent protection in the US.

What happened with the Volpara share price?

Volpara told investors that it has been granted another patent in the US, which protects the unique features of the company’s VolparaEnterprise and VolparaLive! software.

This is the latest patent protection that has been granted internationally.

The company uses a combination of intellectual property rights, which includes patents, trade secrets, copyright and trademarks, to ensure effective, enforceable protection of its products and to help its sales and growth strategy.

Management comments

The CEO of Volpara, Dr Ralph Highnam, said: “The patent granted by the US patent and trademark office protects key features of our current products, and the advantages that those products offer clinicians and patients.

The patent also protects developments that Volpara will integrate into new products. It helps secure our freedom to operate and build upon our foundation patients, which are now approaching 12 years since grant.”

Summary thoughts

Volpara is probably one of the highest quality ASX growth shares around, so having more patent protections for its services gives it more protection against competition. I think the Volpara share price could be a good idea for a long term investment.

The healthcare business has a very promising future, particularly if it can keep increasing its average revenue per user (ARPU).

1 ASX Stock to Buy RIGHT NOW...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: